Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
Latest Releases
- Cognizant Study Shows Consumers Who Embrace AI Could Drive $4.4 Trillion in Spending Over Five Years
- SD’s Products Shine as a Highlight of Light Middle East 2025, Joining Tuya Ecosystem Partner Exhibition to Advance Global Market Expansion
- ARK Wealth Black and Diamond Client Summit: Enhancing Wealth Allocation Strategies for a New Era
- MINISO Group Announces Results of Extraordinary General Meeting
- Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)
- ChargePoint Leads Fights Against Industry-Wide EV Charger Cable Theft with Anti-Vandalism Solutions
- CrowdStrike Falcon® Identity Protection Delivered $1.26 Million in Total Benefits Over Three Years, with Payback Period of Under Six Months
- MetroCity Bankshares, Inc. Declares Quarterly Cash Dividend
- Azitra Announces Proposed Public Offering of Common StockAzitra Announces Proposed Public Offering of Common Stock
- Comcast Activates $7M State-of-the-Art Network in Kingsland, Georgia